Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.

Mohammed AlshalalfaHatem Abou-OufElai DavicioniR Jeffrey KarnesReda AlhajjTarek A Bismar

Published in: Journal of cancer research and clinical oncology (2021)

ISL1 complex with MEIS2 serves a critical role in prostate tumor progression and its upregulation in mCRPC/NE provides a rationale for assessing the role of ISL1 and its associated protein in treatment resistance.

Keyphrases

prostate cancer
poor prognosis
radical prostatectomy
long non coding rna
clinical trial
cell proliferation
combination therapy
benign prostatic hyperplasia
smoking cessation